| Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019 LM Haile, K Kamenov, PS Briant, AU Orji, JD Steinmetz, A Abdoli, ... The Lancet 397 (10278), 996-1009, 2021 | 798 | 2021 |
| Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis JS Nirwan, SS Hasan, ZUD Babar, BR Conway, MU Ghori Scientific reports 10 (1), 5814, 2020 | 342 | 2020 |
| Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries T Gammie, CY Lu, ZUD Babar PloS one 10 (10), e0140002, 2015 | 318 | 2015 |
| Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia ZUD Babar, MIM Ibrahim, H Singh, NI Bukahri, A Creese PLoS medicine 4 (3), e82, 2007 | 270 | 2007 |
| Drug shortage: causes, impact, and mitigation strategies S Shukar, F Zahoor, K Hayat, A Saeed, AH Gillani, S Omer, S Hu, ... Frontiers in pharmacology 12, 693426, 2021 | 242 | 2021 |
| Pharmacists at the frontline beating the COVID-19 pandemic N Bukhari, H Rasheed, B Nayyer, ZUD Babar Journal of pharmaceutical policy and practice 13, 1-4, 2020 | 218 | 2020 |
| How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries S Vogler, V Paris, A Ferrario, VJ Wirtz, K de Joncheere, P Schneider, ... Applied health economics and health policy 15, 307-321, 2017 | 202 | 2017 |
| Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study S Vogler, A Vitry The Lancet Oncology 17 (1), 39-47, 2016 | 200 | 2016 |
| COVID-19 and risks to the supply and quality of tests, drugs, and vaccines PN Newton, KC Bond, M Adeyeye, M Antignac, A Ashenef, GR Awab, ... The Lancet Global Health 8 (6), e754-e755, 2020 | 164 | 2020 |
| An evaluation of consumers’ knowledge, perceptions and attitudes regarding generic medicines in Auckland ZUD Babar, J Stewart, S Reddy, W Alzaher, P Vareed, N Yacoub, ... Pharmacy world & science 32, 440-448, 2010 | 163 | 2010 |
| Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1 NC Galles, PY Liu, RL Updike, N Fullman, J Nguyen, S Rolfe, AN Sbarra, ... The Lancet 398 (10299), 503-521, 2021 | 159 | 2021 |
| Understanding the factors influencing healthcare providers’ burnout during the outbreak of COVID-19 in Jordanian hospitals A Algunmeeyn, F El-Dahiyat, MM Altakhineh, M Azab, ZUD Babar Journal of pharmaceutical policy and practice 13, 1-8, 2020 | 141 | 2020 |
| Management of COVID-19 vaccines cold chain logistics: a scoping review ML Fahrni, IAN Ismail, DM Refi, A Almeman, NC Yaakob, KM Saman, ... Journal of pharmaceutical policy and practice 15 (1), 16, 2022 | 132 | 2022 |
| Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019 GBD 2019 Collaborators, E Nichols, F Abd‐Allah, A Abdoli, AE Abosetugn, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 7 (1 …, 2021 | 122 | 2021 |
| Impact of tuberculosis treatment on health-related quality of life of pulmonary tuberculosis patients: a follow-up study M Atif, SA Syed Sulaiman, AA Shafie, M Asif, MK Sarfraz, HC Low, ... Health and quality of life outcomes 12, 1-11, 2014 | 122 | 2014 |
| Evaluating pharmacists’ views, knowledge, and perception regarding generic medicines in New Zealand P Grover, J Stewart, M Hogg, L Short, HG Seo, A Rew Research in Social and Administrative Pharmacy 7 (3), 294-305, 2011 | 120 | 2011 |
| Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019 JR Ledesma, J Ma, A Vongpradith, ER Maddison, A Novotney, MH Biehl, ... The Lancet Infectious Diseases 22 (2), 222-241, 2022 | 117 | 2022 |
| The availability, pricing and affordability of three essential asthma medicines in 52 low-and middle-income countries ZUD Babar, C Lessing, C Mace, K Bissell Pharmacoeconomics 31, 1063-1082, 2013 | 111 | 2013 |
| Herbal medicines: a cross-sectional study to evaluate the prevalence and predictors of use among Jordanian adults F El-Dahiyat, M Rashrash, S Abuhamdah, R Abu Farha, ZUD Babar Journal of pharmaceutical policy and practice 13 (1), 2, 2020 | 105 | 2020 |
| Availability, affordability, access, and pricing of anti-cancer medicines in low-and middle-income countries: a systematic review of literature P Ocran Mattila, R Ahmad, SS Hasan, ZUD Babar Frontiers in Public Health 9, 628744, 2021 | 100 | 2021 |
Syed Shahzad HasanUniversity of Huddersfield, UKVerified email at hud.ac.uk